

DRUG PRIOR AUTHORIZATION COMMITTEE

September 21, 2017

AGENDA

Department of Natural Resources
1101 Riverside Dr.
Lacharette/Nightingale Rooms
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Steve Calloway/Mitch Ruth
10:25 - 10:35	DUR Update	Steve Calloway

Old Business

10:35 – 10:45	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Steve Calloway
---------------	--	----------------

B. Follow-up Decisions from June 15, 2017 Drug Prior Authorization Committee Meeting

I. Targeted Immune Modulators PDL

- Discussion
- Public Hearing
- Decision

II. Insulins: Rapid-Acting PDL

- Discussion
- Public Hearing
- Decision

III. AntiDiabetic Combinations PDL: Oral and Injectables

- Discussion
- Public Hearing
- Decision

New Business

10:45 – 11:30	C. Proposed Actions - New Drug/Product Review (See website and Attached Summary)	Steve Calloway
---------------	--	----------------

I. Open Access

II. Clinical Edit/Step Therapy

III. PDL Products

Prior Authorization

- Discussion
- Public Hearing
- Decision

11:30 – 11:45

D. Clinical Edits

I. Short-Acting Opioids Clinical Edits

- Discussion
- Public Hearing
- Decision

II. Opiate Dependence Agents PDL (Approval Criteria)

- Discussion
- Public Hearing
- Decision

III. Emflaza® Clinical Edit

- Discussion
- Public Hearing
- Decision

IV. Tymlos®/Forteo® Clinical Edit

- Discussion
- Public Hearing
- Decision

V. Bidil® Clinical Edit

- Discussion
- Public Hearing
- Decision

11:45 – 1:00

E. Preferred Drug List (PDL)

I. ACE Inhibitor Agents

- Discussion
- Public Hearing
- Decision

II. ACE Inhibitors/Calcium Channel Blocker Combination Agents

- Discussion
- Public Hearing
- Decision

III. ACE Inhibitors/Diuretic Combination Agents

- Discussion
- Public Hearing
- Decision

IV. Angiotensin Receptor Blocker Agents (ARB's)

- Discussion
- Public Hearing
- Decision

V. Angiotensin Receptor Blocker/Diuretic Combination Agents

- Discussion
- Public Hearing
- Decision

- VI. Angiotensin Receptor/Calcium Channel Blocker Combination Agents**
 - Discussion
 - Public Hearing
 - Decision
- VII. Anticoagulant Agents: Oral and Subcutaneous**
 - Discussion
 - Public Hearing
 - Decision
- VIII. Antiplatelet Agents**
 - Discussion
 - Public Hearing
 - Decision
- IX. Beta Adrenergic Blockers and Diuretic Combination Agents**
 - Discussion
 - Public Hearing
 - Decision
- X. Calcium Channel Blocker Agents (Dihydropyridines)**
 - Discussion
 - Public Hearing
 - Decision
- XI. Calcium Channel Blocker Agents (Non-Dihydropyridines)**
 - Discussion
 - Public Hearing
 - Decision
- XII. Direct Renin Inhibitors and Combination Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIII. Hepatitis C Therapy: Direct-Acting Antiviral Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIV. Homozygous Familial Hypercholesterolemia Products**
 - Discussion
 - Public Hearing
 - Decision
- XV. Lipotropic Agents: Niacin and Combination Preparations**
 - Discussion
 - Public Hearing
 - Decision

XVI. Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products

- Discussion
- Public Hearing
- Decision

XVII. Proton Pump Inhibitor Agents

- Discussion
- Public Hearing
- Decision

XVIII. Pulmonary Hypertension Agents: Inhaled/Injectable

- Discussion
- Public Hearing
- Decision

XIX. Pulmonary Hypertension Agents: Oral

- Discussion
- Public Hearing
- Decision

XX. Sympatholytic Antihypertensive Agents

- Discussion
- Public Hearing
- Decision

XXI. Triglyceride Lowering Agents

- Discussion
- Public Hearing
- Decision

F. Preferred Drug List Classes for Dec/Jan

- Process Discussion
- Therapeutic classes/to be announced at meeting

1:00

LUNCH

1:15-1:30

G. Program Utilization Information - Conduent Update

Luke Boehmer

1:30-1:50

H. Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: December 14, 2017

James C. Kirkpatrick State Information Center

600 W. Main Street, Conf Rm 139, Jefferson City, MO